NASDAQFinancialsInsurance BrokersSnapshot 2026-07-09
Reading LIFE? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →QuarterlyIQ Insights · LIFE
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-07-11. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $20 the market pays 24× p/e — above the 12× p/e peer median but in line with its own 22× history. That premium reflects a durable franchise our peer-anchored $18 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts target $26–$30. Note: our $18 fair value sits below the entire analyst range ($26–$30). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $27.00 | — | — | Analyst | high |
| graham number | 12M | $13.16 | — | — | TTM | high |
| Peer P/B | 12M | $11.96 | 1.3 | 9.17 | TTM | high |
| Peer P/E | 12M | $18.39 | 11.1 | 1.65 | ntm analyst | high |
| PEG | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
$26.00 – $30.00 (median $27.00) · 3 analysts · as of 2026-05-14
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Around its own typical valuation.
| $16.35 |
| 19.5 |
| 0.84 |
| TTM |
| high |
| residual income | 12M | $9.29 | — | — | TTM | high |
| Own P/E history | 12M | $18.14 | 21.6 | 0.84 | TTM | high |
| triangulated | 12M | $10.54 | 12.3 | 0.86 | Triangulated | high |
| Peer P/E | 3Y | $24.32 | 11.1 | 2.18 | Analyst | medium |
| PEG | 3Y | $24.86 | 19.5 | 1.28 | Analyst | medium |
| Own P/E history | 3Y | $27.59 | 21.6 | 1.28 | Analyst | medium |
| Peer P/E | 5Y | $32.17 | 11.1 | 2.89 | Analyst | high |
| PEG | 5Y | $32.88 | 19.5 | 1.69 | Analyst | high |
| Own P/E history | 5Y | $36.49 | 21.6 | 1.69 | Analyst | high |
